Patient Information
A 38-year-old male presented to the ophthalmology clinic with a 10-day history of bilateral blurred vision, accompanied by recent onset headaches and auditory disturbances. He reported no prior ocular trauma or infections. His past medical history was unremarkable, and there was no family history of autoimmune or inflammatory diseases. On systemic examination, no rash or skin depigmentation was noted at presentation.
Diagnosis
Ophthalmic examination revealed bilateral granulomatous anterior uveitis and multiple serous retinal detachments on fundoscopy. Optical coherence tomography (OCT) confirmed subretinal fluid. Neurological evaluation noted mild sensorineural hearing loss, and brain MRI demonstrated nonspecific meningeal enhancement. Based on clinical features including bilateral panuveitis, neurological symptoms, and auditory involvement, the diagnosis of Vogt-Koyanagi-Harada (VKH) syndrome was established. This multisystem autoimmune disorder targets melanocyte-rich tissues including the eyes, inner ear, and meninges.
Differential Diagnosis
Differential considerations included:
– Sympathetic ophthalmia: typically follows ocular trauma or surgery, which was absent.
– Multiple sclerosis: neurological symptoms present but ophthalmic findings and auditory symptoms were atypical.
– Sarcoidosis: can cause uveitis and neurological symptoms but chest imaging and serum ACE levels were normal.
– Infectious causes (e.g., syphilis, tuberculosis): infectious workup including serologies was negative.
Treatment and Management
The patient was initiated on high-dose systemic corticosteroids (oral prednisone 1 mg/kg/day) to control inflammation. Adjunctive immunosuppressive therapy with azathioprine was started to reduce steroid exposure and prevent relapses. Topical corticosteroids and cycloplegic agents were used to manage ocular inflammation and prevent synechiae. Audiological follow-up and neurological monitoring were arranged. The therapeutic approach aligned with current guidelines advocating prompt aggressive immunosuppression in VKH to prevent irreversible visual and neurological sequelae.
Outcome and Prognosis
The patient demonstrated significant improvement within 4 weeks, with resolution of serous retinal detachments and visual acuity returning to baseline. Auditory symptoms improved but mild hearing deficits persisted. Systemic corticosteroids were tapered gradually over 6 months, while azathioprine was continued for maintenance. At 12-month follow-up, no relapses were observed. Prognosis in VKH depends on early diagnosis and treatment; this patient’s timely management favored a favorable visual and neurological outcome.
Discussion
This case highlights the importance of recognizing VKH syndrome, an autoimmune condition targeting melanocyte-containing tissues, which presents with multisystem symptoms including bilateral granulomatous uveitis, neurological, and auditory manifestations. Early diagnosis is critical as untreated VKH can lead to progressive vision loss, hearing impairment, and neurological complications. The differential diagnosis includes other causes of uveitis and neurological disorders; however, the combination of ocular, auditory, and meningeal symptoms is characteristic.
Treatment predominantly involves systemic corticosteroids to induce remission, supplemented with immunosuppressants for long-term control and prevention of relapses. Multidisciplinary management involving ophthalmologists, neurologists, and otolaryngologists optimizes outcomes.
This patient’s presentation and treatment reinforced existing literature advocating aggressive initial immunosuppression to improve prognosis. Awareness of VKH is essential for timely intervention to preserve vision and neurological function.
References
1. Read RW, et al. Vogt-Koyanagi-Harada disease. Ophthalmology. 2001;108(10):1869-78.
2. Rao NA, et al. Diagnosis and management of Vogt-Koyanagi-Harada disease. Int Ophthalmol Clin. 2014;54(2):97-107.
3. Moorthy RS, et al. Vogt-Koyanagi-Harada syndrome. Surv Ophthalmol. 1995;39(4):265-92.